AIM: @entity737 ( @entity737 ) reduce arrhythmic mortality in a wide range of @entity1 with poor left ventricular (LV) function. However, whether @entity737 therapy is equally effective in younger and older @entity1 remains uncertain. To address this question, we compared @entity737 -documented @entity1165 burden in @entity1 < 75 years of age (Group 1) and >or= 75 years of age (Group 2). METHODS: Data were obtained from 208 consecutive @entity737 -treated @entity1 : 159 Group 1 (mean age 59 +/- 12), and 49 Group 2 (mean age 79 +/- 3). Demographic and clinical features including presenting @entity943 , LV ejection fraction, and nature of @entity299 were similar. Medications were comparable except that @entity2643 use was more frequent in Group 2. RESULTS: The numbers of combined @entity1165 ( @entity1165 ) and @entity2224 ( @entity2224 ) episodes per month were 0.4 +/- 2 and 0.3 +/- 2 for groups 1 and 2, respectively (P = 0.7). Individually, @entity1165 episodes per month were 0.4 +/- 2 and 0.3 +/- 2 (P = 0.7) and @entity2224 episodes per month were 0.003 +/- 0.01 and 0.03 +/- 0.2 (P = 0.2) for the two groups, respectively. The mean duration and average cycle length of @entity943 were 3.1 +/- 20.4 s and 275 +/- 119 ms in Group 1, and 6 +/- 45 s and 285 +/- 114 ms in Group 2 (P values, 0.6 and 0.8). The mean time between the @entity737 implantation and the first episode of a device-treated @entity943 was comparable in the two groups. Thirty-six @entity1 died during follow-up; 22 (14%) Group 1 and 14 (29%) Group 2 (P = 0.02), almost exclusively on a non-sudden cardiac basis. Thus, despite higher ultimate mortality in older @entity1 , both the nature and characteristics of spontaneous @entity943 recurrence, and the time to first apparently beneficial therapy, were similar during follow-up in the two groups. CONCLUSION: In terms of reversing potentially life-threatening @entity943 , the rationale for @entity737 therapy is comparable in older and younger individuals.

Comparison of XXXX burden, therapeutic interventions, and survival, in @entity1 < 75 and @entity1 >or= 75 years of age treated with implantable cardioverter defibrillators.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['VT', 'ventricular tachycardia', 'ventricular tachyarrhythmia'] @entity737 :: ('MESH:D057873', 'Disease') :: ['Implantable cardioverter defibrillators', 'ICD'] @entity2224 :: ('MESH:D014693', 'Disease') :: ['VF', 'ventricular fibrillation'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease'] @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias', 'arrhythmia']
@entity943 :: (MESH:D001145,Disease) :: ['ventricular arrhythmia']
